128 related articles for article (PubMed ID: 3308479)
1. The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy.
Fish RG; Shelley MD; Maughan T; Rocker I; Adams M
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):831-5. PubMed ID: 3308479
[TBL] [Abstract][Full Text] [Related]
2. CA125 in ovarian tumour tissue at second laparotomy.
Maughan TS; Fish RG; Shelley MD; Jasani B; Williams GT; Adams M
Br J Cancer; 1989 Feb; 59(2):259-60. PubMed ID: 2649131
[No Abstract] [Full Text] [Related]
3. Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary.
Maughan TS; Fish RG; Shelley M; Jasani B; Williams GT; Adams M
Gynecol Oncol; 1988 Jul; 30(3):342-6. PubMed ID: 2839394
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an immunoradiometric assay for the detection of an ovarian tumour marker, CA125, in serum.
Shelley MD; Fish RG
Ann Clin Biochem; 1986 May; 23 ( Pt 3)():292-6. PubMed ID: 3466568
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.
Canney PA; Moore M; Wilkinson PM; James RD
Br J Cancer; 1984 Dec; 50(6):765-9. PubMed ID: 6208925
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
Reed E; Ostchega Y; Steinberg SM; Yuspa SH; Young RC; Ozols RF; Poirier MC
Cancer Res; 1990 Apr; 50(8):2256-60. PubMed ID: 2180564
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma].
Iwasaka T; Ohkuma Y; Yoshimura T; Sugimori H
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):917-23. PubMed ID: 2426378
[TBL] [Abstract][Full Text] [Related]
8. Initial assessment of tumor-associated antigen CA-125 in patients with ovarian, cervical, and testicular tumors.
Buamah PK; Cornell C; Skillen AW; Cantwell BM; Harris AL
Clin Chem; 1987 Jul; 33(7):1124-5. PubMed ID: 3036401
[TBL] [Abstract][Full Text] [Related]
9. Tumour-associated antigen CA 125 in patients with ovarian cancer.
Heinonen PK; Tontti K; Koivula T; Pystynen P
Br J Obstet Gynaecol; 1985 May; 92(5):528-31. PubMed ID: 3857939
[TBL] [Abstract][Full Text] [Related]
10. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.
Lund B; Hansen M; Hansen OP; Hansen HH
J Clin Oncol; 1989 Oct; 7(10):1469-73. PubMed ID: 2674334
[TBL] [Abstract][Full Text] [Related]
11. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
[TBL] [Abstract][Full Text] [Related]
12. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
Hills CA; Kelland LR; Abel G; Siracky J; Wilson AP; Harrap KR
Br J Cancer; 1989 Apr; 59(4):527-34. PubMed ID: 2653399
[TBL] [Abstract][Full Text] [Related]
13. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin in refractory epithelial ovarian cancer.
Kavanagh JJ; Nicaise C
Semin Oncol; 1989 Apr; 16(2 Suppl 5):45-8. PubMed ID: 2655098
[No Abstract] [Full Text] [Related]
15. Carboplatin versus cisplatin.
Tighe M; Goodman S
Lancet; 1988 Dec; 2(8624):1372-3. PubMed ID: 2904096
[No Abstract] [Full Text] [Related]
16. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
17. CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
Canney PA; Wilkinson PM; James RD; Moore M
Br J Cancer; 1985 Jul; 52(1):131-3. PubMed ID: 2410004
[No Abstract] [Full Text] [Related]
18. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R
J Clin Oncol; 1990 Aug; 8(8):1335-41. PubMed ID: 2199620
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with nedaplatin in patients with ovarian cancer that recurred after platinum-containing chemotherapy: report of two cases.
Itoh K; Yamashita T; Wakita H; Watanabe Y; Kodama K; Fujii H; Minami H; Ohtsu T; Igarashi T; Sasaki Y
Jpn J Clin Oncol; 1998 May; 28(5):343-6. PubMed ID: 9703864
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
